BIOFIRE® SPOTFIRE® RESPIRATORY/SORE THROAT (R/ST) PANEL

1 PCR Test. 2 Uses. 15 Targets. ~15 Minutes.

RESPIRATORY

VIRUSES

- Adenovirus
- Coronavirus SARS-CoV-2
- Coronavirus (seasonal)
- Human metapneumovirus
- Human rhinovirus/enterovirus
- Influenza A virus
  - Influenza A virus A/H1-2009
  - Influenza A virus A/H3
- Influenza B virus
- Parainfluenza virus
- Respiratory syncytial virus

BACTERIA

- *Bordetella parapertussis*
- *Bordetella pertussis*
- *Chlamydia pneumoniae*
- *Mycoplasma pneumoniae*

SORE THROAT

VIRUSES

- Adenovirus
- Coronavirus SARS-CoV-2
- Coronavirus (seasonal)
- Human metapneumovirus
- Human rhinovirus/enterovirus
- Influenza A virus
  - Influenza A virus A/H1-2009
  - Influenza A virus A/H3
- Influenza B virus
- Parainfluenza virus
- Respiratory syncytial virus

BACTERIA

- *Chlamydia pneumoniae*
- *Mycoplasma pneumoniae*
- *Streptococcus dysgalactiae* (group C/G Strep)
- *Streptococcus pyogenes* (group A Strep)

Overall Respiratory performance (NPS specimens): 98.5% PPA, 99.1% NPA[1]
Overall Sore Throat performance (TS specimens): 96.6% PPA, 99.1% NPA[1]

CE 2797

What is syndromic testing?

Syndromic testing refers to a symptom-driven broad grouping of probable pathogens into one, rapid test that maximizes the chance of getting the right answer in a clinically relevant timeframe.

Knowing the pathogen matters.

Rapid and accurate actionable onsite results during a patient visit may impact patient therapy and management decisions.



One sample

Easy test preparation

PCR results in about 15 minutes

Comprehensive results in a single easy to read report

May impact early therapy decisions and patient management

The value of the syndromic approach for Point-of-Care Testing (POCT).

Inform Clinical Decisions

Testing for more than flu, RSV, and SARS-CoV-2 with one test provides healthcare professionals with the full picture. Comprehensive results in a clinically actionable timeframe may inform a definitive diagnosis, optimize care, and support antimicrobial stewardship.



Improve Patient Satisfaction

Administering one swab, on one test that detects multiple pathogens may result in reduced follow-up appointments, swabbing, and testing, which could improve patient comfort, experience, and convenience.

Optimize Operations

The simplified workflow and quick turnaround time of the BIOFIRE® SPOTFIRE® System may enable rapid and comprehensive answers, which can be communicated to the patient during the appointment while reducing the need for callbacks or expensive and slow send-out testing.

Is it COVID-19, the flu or something else?

Identifying respiratory bugs has never been more important. But several respiratory bugs can cause similar, overlapping symptoms. Data from BIOFIRE® Syndromic Trends[2] demonstrate that even during conventional flu season, influenza comprised less than one third of detected respiratory pathogens during this period. A comprehensive panel means fewer missed detections.

BIOFIRE Respiratory Pathogen Trends[2]



Panel Information

Sample Type: Nasopharyngeal swab (NPS) or throat swab (TS) in 1 to 3 mL of transport media

Storage Conditions: All kit components stored at room temperature (15-25 °C)

Specimen Transport and Storage: Room temperature for up to 4 hours (15-25 °C), refrigerated for up to 3 days (2-8 °C), or frozen (≤-15 °C) for up to 30 days

Part number

BIOFIRE® SPOTFIRE® Respiratory/Sore Throat Panel kit (30 pouches): 423485

Contact Us

bioMérieux S.A.
69280 Marcy l'Etoile
France
Tel: +33 (0) 4 78 87 20 00
Fax: +33 (0) 4 78 87 20 90
biomerieux.com

Manufactured by:
BioFire Diagnostics, LLC
515 Colorow Drive
Salt Lake City, UT 84108 USA
Tel: +1-801-736-6354
biofiredx.com

Product availability varies by country. Consult your bioMérieux representative.

References

[1] Overall performance based on prospective clinical study for the BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel, data on file, BioFire Diagnostics

[2] http://www.syndromictrends.com / Data generated using BIOFIRE® Respiratory 2.1 (RP2.1) Panel in acute inpatient settings in US only.

9325422 007/GB/B / BFR0002-4235-02